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Abstract
Background: The metabolic syndrome (MetSyn) places individuals at increased risk for type 2 diabetes and
cardiovascular disease. Prevalence rates of the population of the MetSyn are still scarce. Moreover, the impact of
different definitions of the MetSyn on the prevalence is unclear. Aim here is to assess the prevalence of the MetSyn
in primary health care and to investigate the impact of four different definitions of the MetSyn on the determined
prevalence with regard to age, gender and socio-economic status.
Methods: The German-wide cross-sectional study was conducted during two weeks in October 2005 in 1.511
randomly selected general practices. Blood samples were analyzed, blood pressure and waist circumference
assessed, data on lifestyle, medication, chronic disorders, and socio-demographic characteristics collected.
MetSyn prevalence was estimated according to the definitions of NCEP ATP III (2001), AHA/NHLBI (2004, 2005),
and IDF (2005). Descriptive statistics and prevalence rate ratios using the PROG GENMOD procedure, were
calculated. Cohen's kappa was used as measure for interreliability between the different prevalence estimates.
Results: Data of 35,869 patients (age range: 18–99, women 61.1%) were included. The prevalence was lowest
using the NCEP ATP III- (all: 19.8%, men 22.7%, women: 18.0%), highest according to the IDF-definition (32.7%,
40.3%, 28.0%). The increase in prevalence with recent definitions was more pronounced for men than for women,
and was particularly high for men and women aged 60–79 years. The IDF-definition resulted in a higher prevalence
especially in those with the highest educational status. Agreement (kappa) between the NCEP ATP III- and IDF-
definition was 0.68 (men 0.61, women 0.74), between the updated the AHA/NHLBI- (2005) and IDF-definition
0.85 (men 0.79, women 0.89).
Conclusion: The prevalence of metabolic syndrome is associated with age, gender, and educational status and
increases considerably with each newly published definition. Our data highlight the need for a better evidence
regarding thresholds of the components of the metabolic syndrome, especially with regard to the IDF-definition
– according to which in some populations a majority of subjects are diagnosed with the metabolic syndrome.
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Background
Over the past decade the Metabolic syndrome (MetSyn)
has been granted increased attention due to its postulated
impact on cardiovascular diseases, especially if linked to
the increasing problem of (central) adiposity.
There are many different terms – Syndrome X, Deadly
Quartet, Plurimetabolic Syndrome, Insulin Resistance
Syndrome, or recently Cardiometabolic Syndrome – for
the Metabolic syndrome and many faces of the Metabolic
Syndrome, since almost every other year in the last 8 years
a new definition for diagnosis of MetSyn has been
released (Tab. 1). The most widely used is the National
Cholesterol Education Program Adult Treatment Panel III
(NCEP ATP III) definition [1]. In contrast to the definition
of the World Health Organization (WHO) [2], it does not
require the determination of insulin levels, thereby facili-
tating prevalence assessment. In 2004 and 2005, the
NCEP ATP III-definition has been modified by the Amer-
ican Heart Association and the National Heart, Lung, and
Blood Institute (AHA/NHLBI) [3,4]. In 2005, the major
adjustment to the AHA/NHLBI 2004 definition was to
include persons reporting a history of current antihyper-
tensive drug or lipid lowering medication use regardless
of measured values (Tab. 2).
Also in 2005, and prior to the release of the 2005 revision
of the AHA/NHLBI-definition, the International Diabetes
Federation (IDF) announced a new, meant to be globally
applicable "platinum standard" definition of the MetSyn
[5]. The IDF sharply reduced the cutoff value for central
adiposity and made central adiposity as a prerequisite to
the diagnosis of the MetSyn [6]. One of the rationale of
this definition was to provide a standard definition that
could enable better comparisons between studies with a
standardized clinical diagnose.
The use of different definitions might have an impact on
the determined prevalence and confuses the interpreta-
tion of epidemiological studies. While earlier studies on
the prevalence of the MetSyn primarily used the WHO
and EGIR definitions, most recent studies have used the
NCEP ATP III-definition.
An aggravating factor is that to date populationwide data
about precise frequencies and distributions of the MetSyn
occurrence is still missing and only few studies have used
the IDF-definition to estimate the prevalence of the Met-
Syn [7]. Furthermore, to our knowledge, there is only few
data available, showing the effect of more than two defi-
nitions on the prevalence of the MetSyn in the popula-
tion, especially with their possible impact of different
subgroups.
The German metabolic and cardiovascular risk project
(GEMCAS) is based on a nationwide prevalence study to
assess the MetSyn in a primary care patient population,
with emphasis on the young (<40 years) and elderly
(>75), an often disregarded population group in epidemi-
ological and clinical studies. The aim of this study was (1)
to assess the prevalence of the Metabolic syndrome in Ger-
many in a primary health care setting, (2) to assess the
impact of the NCEP ATP III-, AHA/NHLBI- and IDF-defi-
nitions on the overall prevalence rate, and (3) to deter-
mine the impacts of these definitions on prevalence rates
with regard to age, gender and educational status.
Methods
GEMCAS, a cross-sectional study, was conducted during
two weeks in October 2005 at 1,511 randomly selected
general health care practices across Germany. Practition-
ers specialized in cardiology and/or diabetes were
excluded to prevent results biased toward false higher
prevalence, since especially patients with diabetes and
CVD attend these physicians.
Study methods have been described in detail [8]. In short,
all eligible patients aged ≥ 18 years visiting a general prac-
titioner were included in the study population if they gave
their written informed consent. The study protocol was
approved by the institutional ethics committee.
All parameters required for diagnosis of MetSyn were
assessed: waist circumference, blood pressure, glucose,
triglyceride and HDL-cholesterol levels. To account for the
effect of fasting status, a 2-step approach was used. A
blood glucose quick test was performed to distinguish dia-
betic (>11.1 mmol/L) and nondiabetic (<5.58 mmol/L)
patients even under nonfasting conditions. This was done
to minimize the need for follow-up appointments, as only
17% of all participants were able to provide a fasting
blood sample on the survey day. However, blood glucose
concentrations between 5.56–11.1 mmol/L in the quick
test required a follow up fasting blood sample. Addition-
ally, to assess intra-individual variability, 30% of the
study population was scheduled for a follow-up visit irre-
spective of the result of their blood glucose quick test. All
blood samples were analyzed by a central laboratory (Ber-
lin, Germany).
Data were collected on sociodemographic variables,
smoking habits, lifestyle aspects and on a history of cardi-
ovascular disease (CVD) and diabetes. For quality assur-
ance, a monitoring concept including telephone-
monitoring and selective random on-site monitoring was
performed. Non-responder information were collected
including age, sex, obesity, reason for visiting the general
practitioner, and reason for not participating.Cardiovascular Diabetology 2007, 6:22 http://www.cardiab.com/content/6/1/22
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To evaluate the impact of different criteria and cutoff val-
ues for diagnosing the MetSyn, the prevalence was
assessed using NCEP ATP III-, AHA/NHLBI- and IDF-defi-
nitions. Since numerous studies using the NCEP ATP III-
definition included hypertensive treatment, although
explicitly not mentioned in the original definition (Tab.
2), we additionally considered subjects using hyperten-
sive medication as having MetSyn (modified NCEP ATP
III-definition).
Descriptive statistics (mean, standard deviation, 95%-
confidence interval) and prevalence rate ratios (PRR),
using PROG GENMOD procedure, were calculated.
Cohen's kappa was used as measure for interreliability
between the different prevalence estimates. As the sam-
ples were clustered with respect to the physicians offices
reporting the health status of several patients, the Taylor
expansion method was used for analysis, applying the SAS
procedures SURVEYFREQ and SURVEYMEANS.
Results
Characteristics of the study population
The study population has been described in detail [8].
Briefly, 35,869 patients (38.9% men, 61.1% women), age
range 18–99 years were included in the analysis. Mean age
was 53.0 ± 15.8 years for men, women 51.9 ± 16.2 (Tab.
3). A history of diabetes was reported by 17% of all men
(women 10%). Almost 30% of the male and 24% of the
female German population attending a GP were active
smokers. The overall unemployed rate was 10.2%, the
same as the official unemployment rate at October 2005
in Germany (10.4% Federal Statistic Office), indicating a
good representativeness of the study population to the
general German population with regard to social status.
Prevalence of the Metabolic Syndrome by NCEP ATP III 
2001
The crude prevalence for the whole study sample was
according to the most widely used definition NCEP ATP
III (2001) 19.8% (men 22.7%, women 18.0%), age-
standardized according to the German population 18.7%,
(19.5%,18.05). The prevalence of the MetSyn increased
with increasing age up to 70–75 years and was higher
among men than among women up to the age of 65 years
(figure 1). In patients >70 years, women were more often
diagnosed than men.
MetSyn was diagnosed considerably more frequently
among patients with <10 years of school education, with
an higher difference found in women (Tab. 4). The age-
specific prevalence in the lowest educational level was 1.7-
to 3.0-fold higher in women (men: 1.5- to 2.0-fold) when
compared to patients with >10 years of schooling.
Prevalence of the Metabolic Syndrome according to 
different definitions
The age-standardized prevalence of the whole study sam-
ple was lowest when assessed using the NCEP ATP III-
(18.7%), highest using the IDF-definition (30.7%), (see
Additional File 1). The pattern of distribution according
to age and sex remains similar regardless of the definition
used (Fig. 1).
Overview of the distribution of prevalence estimates of the  Metabolic Syndrome by age-group and sex according to dif- ferent definitions Figure 1
Overview of the distribution of prevalence estimates of the 
Metabolic Syndrome by age-group and sex according to dif-
ferent definitions.
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Table 1: Timeline of most popular definitions of the Metabolic 
Syndrome
Year Organization
1998 WHO, World Health Organization
1999 EGIR (European Group for the Study of Insulin Resistance)
2001 NCEP ATP III (National Cholesterol Education Program/
Adult Treatment Panel)
2002 ACE (American College of Endocrinology)
2004 AHA/NHLBI (National Heart, Lung, and Blood Institute/
American Heart Ass.)
2005 IDF (International Diabetes Federation)
2005 AHA/NHLBI (National Heart, Lung, and Blood Institute/
American Heart Ass.)Cardiovascular Diabetology 2007, 6:22 http://www.cardiab.com/content/6/1/22
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Although in 2005 the AHA/NHLBI aligned their criteria
with those of the IDF-definition for a better convergence,
a difference in characterizing subjects as having the Met-
Syn is still apparent. We observed an absolute overall dif-
ference between these definitions of 4%, with a maximum
of more than 7% in 50–59 year old men (see Additional
File 1). However, the relative impact is highest for the
youngest age-group, in both men and women. The level of
agreement between the NCEP ATP-III-definition and the
following definitions decreases with each newer defini-
tion proposed, with the lowest accordance to the IDF (see
Additional File 1). The kappa between the newest AHA/
NHLBI- and the IDF-definition (k 0.85, men 0.79, women
0.86) is still below the kappa between NCEP ATP III- and
the AHA-definition released in 2004 (k 0.91). Fig. 2 shows
that the tightened criteria of the IDF give rise to a higher
chance (PRR) to be diagnosed with MetSyn in subjects
who reported a history of myorcardial infarction, stroke or
diabetes as compared to the other definitions. However,
no differences seem to exist regarding risk factors like
employment status, smoking or physically inactivity.
The absolute increase in prevalence was most extreme for
men in the age-group 50–59, for women 60–69 (see Addi-
tional File 1). The impact of changed definitions is higher
for men than women, widening the gender gap: 1.16-fold
higher prevalence rates for men compared to women
using the NCEP ATP III-definition, increasing to 1.20,
1.22 and 1.33 using the AHA/NHLBI-2004, 2005 and
IDF-definition respective.
Regarding education, as proxy for socio-economic status
(SES), use of the IDF-definition also resulted in a higher
prevalence in all levels of education, with highest impact
in those with the highest SES, slightly reducing the gap
between levels of SES (Tab. 4). The overall PRR character-
izing a person as having MetSyn according to years of
schooling decreases in men with <10 years of schooling
from 1.7 (95%-CI 1.5–1.9) according to NCEP-2001 to
Table 2: Exact NCEP ATP-III, AHA/NHLBI and IDF-definitions of the Metabolic Syndrome as originally published
Risk factor NECP ATP III
2001 [1]*
AHA/NHLBI
2004 [3]†
AHA/NHLBI
2005 [4]†
IDF
2005 [5]**
Central/
Abdominal 
obesity (Waist 
circumference)
M >102 cm‡
W > 88 cm ‡
M >102 cm ‡
W > 88 cm ‡
M ≥ 102 cm §,||
W ≥ 88 cm §,||
Must have: Central obesity, defined as WC¶ 
with ethnicity specific values. Europids: 
male ≥ 94 cm, female ≥ 80 cm plus any two 
of following 4 factors:
Blood pressure ≥130/≥85 
mmHg
≥130/≥85 
mmHg
≥130 mm Hg systolic BP, or ≥ 85 
mm Hg diastolic BP, or drug 
treatment for hypertension
≥130 mm Hg systolic blood pressure, or ≥ 85 mm 
Hg diastolic blood pressure, or treatment of 
previously diagnosed hypertension
Fasting glucose 110 mg/dL# 110 mg/dL** ≥100 mg/dL or drug treatment 
for elevated glucose
≥5.6 mmol/L (100 mg/dL) or previously 
diagnosed diabetes. If above 5.6 mmol/L, 
OGTT is strongly recommended but is not 
necessary to define presence of the 
syndrome
Triglycerides 150 mg/dL 150 mg/dL ≥150 mg/dL (1.7 mmol/L) or drug 
treatment for elevated TG††
≥1.7 mmol/L (150 mg/dL) or specific 
treatment for this lipid abnormality 
HDL cholesterol M <40 mg/dL
W <50 mg/dL
M <40 mg/dL
W<50 mg/dL
M <40 mg/dL (0.9 mmol/L)†† W 
<50 mg/dL (1.1 mmol/L)†† or drug 
treatment for reduced HDL-
C‡‡
M <1.03 mmol/L (40 mg/dL) W <1.29 mmol/L (50 
mg/dL) or specific treatment for this lipid 
abnormality
Differences relative to the NCEP ATP III definition are shown in bold ; M = men, W = women
* sometimes referred to as [44]
† often cited as NCEP ATP III definition
**see also [6]
§ changed from ">" to "≥"
† † erratum in: Circulation. 2005 Oct 25;112(17):e297 and e298 (1.03 and 1.3 mmol/L) for apparently wrong original published values;
Following remarks are all citations of the original definitions:
‡ Overweight and obesity are associated with insulin resistance and the metabolic syndrome. However, the presence of abdominal obesity is more 
highly correlated with the metabolic risk factors than is an elevated BMI. Therefore, the simple measure of WC is recommended to identify the 
body weight component of the metabolic syndrome
|| Lower WC cut point (eg, ≥ 90 cm in men and ≥ 80 cm in women) appears to be appropriate for Asian Americans
¶if BMI is >30, central obesity can be assumed and waist circumference does not need to be measured
# "... the presence of type 2 diabetes does not exclude a diagnosis of metabolic syndrome."
** "The ADA has recently established a cutpoint of ≥ 100 mg/dL, above which persons have either prediabetes (impaired fasting glucose) or 
diabetes. This new cutpoint should be applicable for identifying the lower boundary to define an elevated glucose as one criterion for the metabolic 
syndrome"
‡‡ Fibrates and nicotinic acid are the most commonly used drugs for elevated TG and reduced HDL-C. Patients taking 1 of these drugs presumed to 
have high TG and low HDL.Cardiovascular Diabetology 2007, 6:22 http://www.cardiab.com/content/6/1/22
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1.3 (1.2–1.4), in women 2.2 (2.0–2.4) to 1.8 (1.6–1.9). A
similar observation was made regarding the employment
status (figure 2).
Discussion
The results of this nationwide prevalence study show (1)
a high prevalence of the metabolic syndrome in the Ger-
man primary care population irrespective of the defini-
tion used, (2) large differences in prevalence rates when
using different definitions, and (3) a varying impact of
age, gender and SES on prevalence of metabolic syndrome
between different definitions used.
The crude prevalence of the whole study population was
19.8% according to the most often used NCEP ATP III-,
23.5% according to AHA/NHLBI 2004-definition (age-
standardized 18.7% and 22.0% respective). In line with
previous published studies is the consistent observation
of a high age dependence of the MetSyn, with a steady
increase up to the age of 60 in some population in men
[9] and 70 to 75 in both men and women in the US pop-
ulation [10], European populations [11,12] or in one Iran
cohort [13].
Most countries reported slightly lower rates, like in an
Irish primary care population [14], an Italian cohort [15]
or a French [16] and Chinese working population [17],
(see Additional File 2).
The prevalence in the US between 1988–1994 is slightly
higher compared to GEMCAS (see Additional File 2). Ford
and colleagues, using data from NHANES, estimated an
age-adjusted prevalence of 23.7% based on a study sam-
ple of 8,814 participants [18]. With the same data set, but
a reduced sample size (6,436), they reported two years
later a prevalence of 24.1% [19]. Comparing data from
NHANES 1988–1994 with newest NHANES data from
1999–2000, they reported a non-significant increase of
the MetSyn among US adults up to 27.0% [19]. Unfortu-
nately it remains recondite why one year later they esti-
mated a prevalence of 34.5% with the same cohort [10].
Probably, different sample sizes ([19]: n = 1677, [10]: n =
3601) might account for these notable differences in the
same cohort, although an indication for possible different
sample selection is not provided. However, with these cur-
rently published prevalence data, a much higher propor-
tion of the US adults seems to be classified as having the
MetSyn compared to our German cohort.
In a sample of 3,589 British women free of CHD ran-
domly selected from general practitioner lists [20], a prev-
alence with respect to the NCEP ATP III-definition of
29.8% was reported (see Additional File 2), which is
much higher compared to 21.0% in GEMCAS women in
the same age-range and free of CHD. However, Lawlor
and colleagues modified the NCEP ATP III-definition by
using the HDL-C threshold for men (<1 mmol/L instead
of <1.3 mmol/L for women). Applying this threshold to
GEMCAS, only 18.4% of the women would have been
classified as having MetSyn.
Table 3: Patients characteristics stratified by sex in GEMCAS
Mean ± SD
Men
N = 13,942
Women
N = 21,927
Age (years) 53.0 ± 15.8 50.9 ± 16.2
BMI (kg/cm2) 27.6 ± 4.4 26.6 ± 5.6
Waist circumference (cm) 98.8 ± 13.0 86.8 ± 14.3
Blood pressure (mmHg)
Systolic 133.6 ± 18.2 128.5 ± 19.3
Diastolic 81.4 ± 10.4 79.2 ± 10.6
Blood sample
Total cholesterol 203 ± 42.4 209 ± 40.8
HDL cholesterol 54.3 ± 14.2 67.3 ± 17.2
LDL cholesterol 128.1 ± 36.6 128.0 ± 36.6
Random blood glucose (mg/dL) 103 ± 36.5 94.7 ± 28.6
8 h fasting blood glucose (mg/dL) 99.7 ± 27.3 93.3 ± 23.6
Random triglycerides (mg/dL) 179.4 ± 164.6 135.2 ± 83.3
12 h fasting triglycerides (mg/dL) 166.3 ± 222.1 129.7 ± 74.3
N (%) 
School years
< 10 years 1205 (8.9) 3927 (18.4)
= 10 years 6914 (50.8) 11993 
(56.2)
> 10 years 5481 (40.3) 5423 (25.4)
Employment
Employed 7130 (52.2) 9726 (45.1)
Unemployed 977 (7.1) 933 (4.3)
Economically inactiveb 5564 (40.7) 10901 
(50.6)
Diabetes mellitus
Type 1 125 (1.0) 99 (0.5)
Type 2 2.197 (16.6) 21.20 (10.1)
History of Cardiovascular 
Disease
Myocardial infarction 1 504 (11.3) 736 (3.54)
Stroke 488 (3.7) 420 (2.0)
Smoker
Yes 3 731 (27.5) 4 993 (23.5)
No, quit 5 395 (39.7) 4 739 (22.3)
No, never 4 445 (32.8) 11 501 
(54.2)
Sport activities
At least 2 h/week 3 528 (26.0) 4 984 (23.3)
Up to 2 h/week 4 886 (36.0) 8 730 (40.9)
No 5 178 (38.2) 7 640 35.8)
a i.e. pupils, students, parents at leave, retireesCardiovascular Diabetology 2007, 6:22 http://www.cardiab.com/content/6/1/22
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Age-adjusted prevalence ratios for different definitions of the Metabolic Syndrome, stratified by sex Figure 2
Age-adjusted prevalence ratios for different definitions of the Metabolic Syndrome, stratified by sex. For each 
definition the prevalence ratio was separately calculated, stratified by sex. Each model included the variables shown in this fig-
ure (CVD, diabetes, employment status, sport activities, smoking) as well as age, vine consumption, educational status. CVD 
and Diabetes mellitus were tested against not having CVD and Diabetes mellitus (reference), for social status employed sub-
jects (reference) were compared with unemployed and economically inactive subjects.
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Our data show the dependence of the estimated occur-
rence of the Metabolic syndrome on their definition used.
However, not only different definitions result in different
prevalence rates, but also crude applications and diverse –
often not indicated – modifications of the original defini-
tions exacerbate this situation (see Additional File 2).
Conspicuous are on one hand minor changes to the defi-
nitions which refer to the use of "≥ " instead of just '>', i.e.
[21]. Sometimes cut-offs even changed by differently
rounding off in SI units (HDL: 39–40 mg/dL equal to 0.9–
1.04 mmol/L or glucose 100–101 mg/dL equal to 5.6
mmol/L, triglyceride ≥ 1.69–1.71 mmol/L equal to 150
mg/dL) i.e. [11,22,23], which in our study changed the
prevalence by 2% to almost 4% respectively. Furthermore,
a common difference is found to be length of fasting
period, reported as "overnight fast", a 6, 8, 12 or 14 hours
to a >12 hours fasting period. Taking only these different
time periods into account, we receive estimates in our
GEMCAS sample ranging between 16–21%.
On the other hand, major changes are the inclusion of
pharmacotherapy as criteria for hypertension or diabetes,
i.e. [10,20,24-28]. Pharmacotherapy is not mentioned in
the original NCEP ATP III- and AHA/NHLBI-definitions
and explicitly not included until the 2005 AHA/NHLBI-
update [4]. Besides, it remains unclear, why most of these
studies included hypertensive medications, but not lipid
lowering drugs. However, subjects who were treated for
hypertension, hypertriglyceridemia, or diabetic in this
study were not defined as hypertensive or diabetes when
using the NCEP ATP-III definition from 2001 and 2004. It
remains an open point of discussion, if this would create
a selection bias leading to an under- or overestimation of
the true prevalence of MetSyn, since the impact of the
MetSyn on developing diabetes mellitus and CVD is still
unclear. Furthermore, the question of drug therapy inclu-
sion certainly depends on the application of the MetSyn,
i.e. if primary prevention issues are of particular interest,
than including treated subject does not make sense.
Further differences like study designs, selection of study
populations, age ranges, measurement methods, and at
latest missing age-standardized prevalence data, make
comparisons of published prevalence rates rather difficult
(see Additional File 2). Subsequently, the majority of
studies reported a wide range of prevalence rates in the
general population and it remains unresolved, if the dif-
ferences between populations are real difference due to
possibly specific genetic constituents, likes and dislikes in
life styles or due to above mentioned methodological
inconsistencies – or all together.
Regarding the difference in prevalence of the MetSyn
between sexes, the picture is contrary to age blurred. In
GEMCAS, prevalence is consistently higher in men in the
age-range 20 to 70. Similar gender differences are found in
Finland [29], Sweden [30], France [12], Italy [15] and in a
pooled European population [31,32]. In contrast, higher
rates in women were reported from Spain [25], Nether-
lands [33], Greenland (Inuit) [21], India [34] and West
Bank [35], whereas almost equal proportions were
reported from the US population [10,25].
Without scrutinizing the whole concept of the MetSyn –
this has been done extensively, [36-38] to name only
some – opinions about the adequate definition to assess
Table 4: Prevalence of the Metabolic Syndrome in GEMCAS according to NCEP ATP III (2001) and IDF (2005) by education status 
(school years), age-group and sex
Age-Group
18–34 35–59 60–99
School
Years
ATP III
2001
IDF
2005
IDF/NCEP ATP III
2001
IDF
2005
IDF/NCEP ATP III
2001
IDF
2005
IDF/NCEP
Men (n = 12,341)
<10 9.5% 10.8% 1.14 30.0% 46.7% 1.56 40.2% 61.3% 1.52
= 10 7.5% 11.1% 1.48 24.5% 40.8% 1.67 31.6% 58.8% 1.86
>10 5.5% 9.3% 1.69 15.4% 30.5% 1.98 26.5% 52.5% 1.98
<10/>10 1.7 1.2 2.0 1.5 1.5 1.2
Women (n = 19,979)
<10 8.8% 10.1% 1.15 25.1% 35.0% 1.39 40.8% 61.1% 1.50
= 10 4.8% 6.4% 1.33 14.1% 21.7% 1.54 29.2% 48.9% 1.67
>10 3.5% 4.7% 1.34 8.3% 14.1% 1.70 24.0% 42.4% 1.77
<10/>10 2.5 2.1 3.0 2.5 1.7 1.4Cardiovascular Diabetology 2007, 6:22 http://www.cardiab.com/content/6/1/22
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the MetSyn are still controversial. Although in 2005 the
IDF released a so called worldwide new definition, the
AHA/NHLBI ensued only some month later with an own,
modified one. In fact, the sets of clinical criteria of both
definitions have converged. In their statement of the AHA
and NHLBI they almost appeal, that despite "minor differ-
ences" both definitions now identify essentially the same
individuals as having the MetSyn, at least in the US popu-
lation [4]. This of course is not false, since almost all indi-
viduals identified as having the MetSyn with the modified
AHA 2005-definition were also identified by the IDF-def-
inition. In GEMCAS only 28 patients (0.1%) were diag-
nosed as having MetSyn with the AHA 2005-definition
but not with the IDF-definition. But this is only the one
aspect. The other aspect, using the IDF-definition, reveals
about 4% more subjects classified as having the syn-
drome, even 7% in men aged 50–80 years, which in GEM-
CAS on its own accounts for an overall additional 1,600
subjects. The agreement (kappa) between the definitions
is still less than 0.9.
The strengths of the study are the sample size, the nation-
wide approach and the assessment of the MetSyn as pri-
mary study target, so comprising all required variables as
original measures. However, the participants are strictly
speaking not a real population-based sample, but close to
being so. Some patients meeting MetSyn criteria might
avoid attending their physician because they are in denial,
in this case an underestimation of the prevalence would
have been occurred. On the other hand, the estimated
prevalence might be too high because the healthy popula-
tion does not routinely visit their physician. However,
91.8% of the adult persons in Germany consult a general
practitioner during one year [39]. Furthermore, the sam-
ple is comparable to other German population-based
samples i.e. with regard to anthropometric measures,
smoking status, marital status and schooling. However,
the proportion of participants with chronic diseases (dia-
betes mellitus, CVD) is higher than compared to popula-
tion-based sample, but still lower than real patient-based
samples [40]. Lastly, this study was conducted and ana-
lysed in line with the way procedures would have been
performed if they had been taken place under real circum-
stances in clinical practices. This report is thus meaningful
because it is the first to provide prevalence rates for the
MetSyn as defined to different definition and to different
subgroups of the population.
Conclusion
These epidemiological data indicate a high prevalence of
the metabolic syndrome in the German population
attending a general practitioner. Especially high rates were
found in older subjects and subjects less well educated.
Concerning prevention issues, the primary scope of appli-
cation of the MetSyn is claimed to be prevention of CVD
and diabetes mellitus. Thus it is questionable to what
extent the most recent definitions are helpful to identify
persons at risk without falsely labelling to much people to
be at risk [41-43], with the postulated consequence of a
rapid and aggressive treatment [5]. Our data highlight the
need for a better evidence regarding thresholds of the
components of the MetSyn, especially with regard to the
IDF-definition – according to which in some subpopula-
tions a majority of subjects are diagnosed with the meta-
bolic syndrome. This could be accomplished by the use of
epidemiological, longitudinal data.
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